The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Previous studies suggest that among patients receiving trastuzumab monotherapy, a HER2/CEP17 ratio \>7.0 (ultra-high expression) is associated with poorer disease-free survival (DFS). Dual-target therapy (trastuzumab + pertuzumab) has become the standard treatment for high-risk HER2-positive breast cancer; however, whether it can predict outcomes in patients with ultra-high HER2 expression remains unsupported by clinical data. To analyze the clinicopathological characteristics and prognostic relationship between the HER2 ultra-high expression group and the normal expression group in non-metastatic HER2-positive breast cancer patients who received dual-target therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjentki w wieku 18 lat i więcej.
- •Rak piersi potwierdzony badaniami, w początkowym stadium (I-III).
- •Rak piersi z wysokim poziomem HER2, potwierdzony specjalistycznym testem.
- •Pacjentki otrzymały co najmniej jedną dawkę leczenia trastuzumabem z pertuzumabem.
- •Pacjentki przeszły operację raka piersi.
✗ Disqualifies
- •Rak piersi z przerzutami do innych narządów (stadium IV) lub rak w obu piersiach jednocześnie.
- •Pacjentki, które wcześniej otrzymywały leczenie anty-HER2.
- •Brak ważnych danych medycznych potrzebnych do badania.
- •Inne nowotwory lub rak piersi niebędący pierwotnym guzem.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- January 29, 2026
- Sex
- Female only
Locations (1)
Department of Medical Oncology
Jinan, China
Trial contact
Fangchao Zheng, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.